FIBROGEN INCKYNBEarnings & Financial Report
FibroGen Inc. is a biopharmaceutical firm developing and commercializing innovative therapies for unmet medical needs, targeting fibrotic diseases, anemia and cancer. Its lead product roxadustat is approved in multiple markets including China and Japan, serving patients across key therapeutic segments.
Revenue
$40.1M
Gross Profit
$35.9M
Operating Profit
$-63.5M
Net Profit
$-63.6M
Gross Margin
89.4%
Operating Margin
-158.2%
Net Margin
-158.5%
YoY Growth
155.1%
EPS
$-0.65
FIBROGEN INC Q3 FY2023 Financial Summary
FIBROGEN INC reported revenue of $40.1M (up 155.1% YoY) for Q3 FY2023, with a net profit of $-63.6M (up 30.6% YoY) (-158.5% margin). Cost of goods sold was $4.2M, operating expenses totaled $99.4M.
Key Financial Metrics
| Total Revenue | $40.1M |
|---|---|
| Net Profit | $-63.6M |
| Gross Margin | 89.4% |
| Operating Margin | -158.2% |
| Report Period | Q3 FY2023 |
FIBROGEN INC Annual Revenue by Year
FIBROGEN INC annual revenue history includes year-by-year totals (for example, 2023 revenue was $46.8M).
| Year | Annual Revenue |
|---|---|
| 2023 | $46.8M |
| 2022 | $140.7M |
FIBROGEN INC Quarterly Revenue & Net Profit History
FIBROGEN INC results over the last 8 reported quarters, including revenue, net profit and year-over-year growth.
| Quarter | Revenue | Revenue YoY | Net Profit | Net Margin |
|---|---|---|---|---|
| Q1 FY2024 | $25.4M | -29.9% | $-32.9M | -129.8% |
| Q4 FY2023 | $-73.8M | -314.8% | $-56.2M | 76.2% |
| Q3 FY2023 | $40.1M | +155.1% | $-63.6M | -158.5% |
| Q2 FY2023 | $44.3M | +48.7% | $-87.7M | -197.8% |
| Q1 FY2023 | $36.2M | -40.6% | $-76.7M | -212.1% |
| Q4 FY2022 | $34.4M | +107.7% | $-66.2M | -192.6% |
| Q3 FY2022 | $15.7M | -89.9% | $-91.7M | -582.5% |
| Q2 FY2022 | $29.8M | +22.3% | $-72.6M | -243.7% |
Income Statement
| Q2 2022 | Q3 2022 | Q4 2022 | Q1 2023 | Q2 2023 | Q3 2023 | Q4 2023 | Q1 2024 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $29.8M | $15.7M | $34.4M | $36.2M | $44.3M | $40.1M | $-73.8M | $25.4M |
| YoY Growth | 22.3% | -89.9% | 107.7% | -40.6% | 48.7% | 155.1% | -314.8% | -29.9% |
Balance Sheet
| Q2 2022 | Q3 2022 | Q4 2022 | Q1 2023 | Q2 2023 | Q3 2023 | Q4 2023 | Q1 2024 | |
|---|---|---|---|---|---|---|---|---|
| Assets | $686.8M | $608.8M | $610.1M | $538.5M | $515.1M | $460.4M | $423.5M | $365.9M |
| Liabilities | $563.0M | $562.6M | $611.6M | $567.4M | $575.4M | $575.6M | $585.7M | $552.0M |
| Equity | $103.8M | $26.3M | $-21.4M | $-48.9M | $-102.3M | $-157.2M | $-204.2M | $-228.1M |
Cash Flow
| Q2 2022 | Q3 2022 | Q4 2022 | Q1 2023 | Q2 2023 | Q3 2023 | Q4 2023 | Q1 2024 | |
|---|---|---|---|---|---|---|---|---|
| Operating CF | $-33.1M | $-51.9M | $-52.5M | $-101.6M | $-110.6M | $-84.5M | $-18.3M | $-59.3M |